Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats

被引:287
作者
Oka, Masahiko
Homma, Noriyuki
Taraseviciene-Stewart, Laimute
Morris, Kenneth G.
Kraskauskas, Donatas
Burns, Nana
Voelkel, Norbert F.
McMurtry, Ivan F.
机构
[1] Univ Colorado, Hlth Sci Ctr, CVP Res Lab, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Pulm Hypertens Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA
关键词
fasudil; vasodilator; vascular remodeling; SU5416;
D O I
10.1161/01.RES.0000261658.12024.18
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vascular remodeling, rather than vasoconstriction, is believed to account for high vascular resistance in severe pulmonary arterial hypertension ( PAH). We have found previously that acute Rho kinase inhibition nearly normalizes PAH in chronically hypoxic rats that have no occlusive neointimal lesions. Here we examined whether Rho kinase - mediated vasoconstriction was also important in a rat model of severe occlusive PAH. Adult rats were exposed to chronic hypoxia ( approximate to 10% O-2) after subcutaneous injection of the vascular endothelial growth factor receptor inhibitor SUGEN 5416. Hemodynamic measurements were made in anesthetized rats after 2 weeks of hypoxia ( early group) and 3 weeks of hypoxia plus 2 weeks of normoxia ( late group). Both groups developed PAH, with greater severity in the late group. In the early group, intravenous fasudil was more effective than intravenous bradykinin, inhaled NO, or intravenous iloprost in reducing right ventricular systolic pressure. Despite more occlusive vascular lesions, fasudil also markedly reduced right ventricular systolic pressure in late-stage rats. Blood-perfused lungs from late-stage rats showed spontaneous vasoconstriction, which was reversed partially by the endothelin A receptor blocker BQ123 and completely by fasudil or Y-27632. Phosphorylation of MYPT1, a downstream target of Rho kinase, was increased in lungs from both groups of rats, and fasudil ( intravenous) reversed the increased phosphorylation in the late group. Thus, in addition to structural occlusion, Rho kinase - mediated vasoconstriction is an important component of severe PAH in SUGEN 5416/hypoxia-exposed rats, and PAH can be significantly reduced in the setting of a severely remodeled lung circulation if an unconventional vasodilator is used.
引用
收藏
页码:923 / 929
页数:7
相关论文
共 48 条
[1]   Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats [J].
Abe, K ;
Shimokawa, H ;
Morikawa, K ;
Uwatoku, T ;
Oi, K ;
Matsumoto, Y ;
Hattori, T ;
Nakashima, Y ;
Kaibuchi, K ;
Sueishi, K ;
Takeshita, A .
CIRCULATION RESEARCH, 2004, 94 (03) :385-393
[2]   The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity [J].
Amano, M ;
Chihara, K ;
Nakamura, N ;
Kaneko, T ;
Matsuura, Y ;
Kaibuchi, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32418-32424
[3]   Targeting Rho and Rho-kinase in the treatment of cardiovascular disease [J].
Budzyn, K ;
Marley, PD ;
Sobey, CG .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (02) :97-104
[4]   Pulmonary hypertension - Cellular and molecular mechanisms [J].
Cool, CD ;
Groshong, SD ;
Oakey, J ;
Voelkel, NF .
CHEST, 2005, 128 (06) :565S-571S
[5]   SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[6]   Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase [J].
Fagan, KA ;
Oka, M ;
Bauer, NR ;
Gebb, SA ;
Ivy, DD ;
Morris, KG ;
McMurtry, IF .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2004, 287 (04) :L656-L664
[7]   Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells [J].
Fukata, Y ;
Amano, M ;
Kaibuchi, K .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (01) :32-39
[8]   Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension [J].
Fukumoto, Y ;
Matoba, T ;
Ito, A ;
Tanaka, H ;
Kishi, T ;
Hayashidani, S ;
Abe, K ;
Takeshita, A ;
Shimokawa, H .
HEART, 2005, 91 (03) :391-392
[9]   The endothelin system in pulmonary arterial hypertension [J].
Galié, N ;
Manes, A ;
Branzi, A .
CARDIOVASCULAR RESEARCH, 2004, 61 (02) :227-237
[10]   Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension [J].
Guilluy, C ;
Sauzeau, V ;
Rolli-Derkinderen, M ;
Guérin, P ;
Sagan, C ;
Pacaud, P ;
Loirand, G .
BRITISH JOURNAL OF PHARMACOLOGY, 2005, 146 (07) :1010-1018